Aim: To describe a case of persistent sub-therapeutic posaconazole levels in setting of salvage chemotherapy for relapsed acute myeloid leukemia. Case details: A 57-year-old male was admitted for the management of relapsed acute myeloid leukemia and ongoing pulmonary aspergillosis. While continuing on posaconazole tablet 300 mg daily, he received a course of salvage chemotherapy. The initial steady state posaconazole trough level was therapeutic at 0.84 mg/L (target >0.70 mg/L). However, after five days, the level had dropped to 0.40 mg/L, coinciding with hyperbilirubinemia and hypoalbuminemia. Bilirubin level peaked at 36 mm/L (normal high <20 mm/L), albumin levels were consistently low, averaging at 25 g/L (range 33-46 g/L). The patient had been compliant and there were no underlying gastrointestinal conditions identified which might have potentially affected posaconazole absorption. Outcome: An increase in posaconazole dose failed to achieve target levels and treatment was changed to voriconazole. However, levels were surprisingly supra-therapeutic, resulting in side effects and substantial dose reduction was required. Conclusion: Failure to achieve target posaconazole levels despite increased dosing may be attributed to factors other than impaired oral absorption. Enhanced metabolism and clearance could be associated with hypoalbuminemia and hyperbilirubinemia. Further case studies, including PK modelling, are required to confirm this effect.
Background
The aim of this study was to describe a case of persistent sub-therapeutic posaconazole levels in setting of salvage chemotherapy for relapsed acute myeloid leukemia (AML). Posaconazole-modified release tablet formulation utilises a pH-sensitive polymer matrix which releases posaconazole only when the pH is adequately elevated. [1] [2] [3] Combined with a secondary effect on drug crystallisation inhibition, this formulation is well absorbed orally, irrespective of food intake and gastric pH. 4 Posaconazole is a potent inhibitor of Cytochrome P450 CYP-3A4 enzyme; however, it is not metabolised to a significant extent by the CYP enzymes. Systemic posaconazole is predominantly metabolised via phase 2 pathways, namely glucuronidation as catalysed by the uridine diphosphate (UDP)-glucuronosyltransferase enzyme. 5 This bio-transformation occurs mainly in liver sites and the gastrointestinal tract. Some data suggest that up to 15% of a dose potentially undergoes metabolism, predominantly via glucuronidation and a small degree by enzymatic oxidation. The oxidised metabolites are either renally cleared or secreted and collected in the colon. 6 Preliminary data reported retrieval of up to 77% of posaconazole in faeces as unchanged parent compound; however, it is not known whether this is unabsorbed original product or a downstream by-product of phase 2 glucuronidated posaconazole.
The significance of phase 2 metabolism of posaconazole has been demonstrated in studies of intentional enhancement of UDP glucuronidation. In these studies, co-administration of posaconazole with inducers of UDP glucuronidation, such as rifabutin and phenytoin, resulted in approximately 40% reduction in posaconazole AUC. 7, 8 Posaconazole is also implicated in the P-glycoprotein (P-gp) pathway, although this is not likely to be of clinical significance. 5 In Phase Ib and III clinical trials, the new tablet formulation was shown to produce more consistent and dependable oral delivery of posaconazole than the oral suspension formulation. 2 As a result, it was suggested that routine therapeutic plasma concentrations monitoring of posaconazole may not be required with the tablet formulation. 2 However, post marketing experience suggests that in clinical practice, other factors may influence attainment of therapeutic levels with both the oral and intravenous (IV) formulation. 9 These cases raise important questions regarding the extent and clinical significance of phase 2 drug metabolism of posaconazole and the contribution of non-drug factors such as hyperbilirubinemia and hypoalbuminemia
Clinical features, intervention, case progress
A 57-year-old male was electively admitted to the hematology unit with relapsed AML. His recent AML treatment included a trial of venetoclax (ABT-199) 600 mg oral daily and cytarabine (20 mg/m 2 ) subcutaneous (SC) daily. Unfortunately, this treatment failed to induce remission. Chemotherapy-induced complications included culture-negative suspected pulmonary aspergillosis, initially requiring treatment with liposomal amphotericin 500 mg IV daily, given drug interaction with the ABT-199 would have contraindicated the use of azole anti-fungals. After five weeks, as ABT-199 had ceased, liposomal amphotericin was switched to posaconazole modified-release tablets 300 mg daily. Other concurrent medications included valaciclovir 500 mg oral twice a day, amoxycillin/ clavulanic acid 875/125 mg oral twice a day (longterm prophylaxis), pantoprazole 40 mg oral daily, prednisolone 5 mg oral daily, and granisetron 2 mg oral daily when required.
After receiving posaconazole for five days, the patient received a course of salvage chemotherapy on day 1, i.e. FLAG-Amsa (Fludarabine 30 mg/m 2 IV at days 1-5, Cytarabine 2000 mg/m 2 IV at days 1-5, Amsacrine 100 mg/m 2 IV at days 1-3, Filgrastim SC 300 mg at days 1-7) and continued anti-fungal therapy. The initial steady-state posaconazole trough level seven days post initiation was therapeutic at 0.84 mg/L (target >0.70 mg/L). A validated reverse phase liquid chromatography-mass spectrometry (LC-MS/MS) with ultraviolet detection on a photodiode array and spectral library matching was used for the plasma posaconazole assay (detectable range 0.10-6.0 mg/mL). This assay measures only 'total' posaconazole concentrations. At the time of writing, target levels for therapeutic therapy were defined as a trough level above 0.7 mg/L. [10] [11] [12] Meanwhile, the patient remained neutropenic (nadir of 0.00 Â 10 9 /L) and recorded high-grade fevers requiring broad-spectrum antibiotic treatment with piperacillin/tazobactam IV 4.5 g four times daily. Blood cultures were positive for Gram-positive rods requiring escalation of treatment to a combination of meropenem 1 g IV three times a day and vancomycin 1 g IV three times a day. Repeat high-resolution computerised tomography (HRCT) scan showed atelectasis and progression of parenchymal changes in both lungs suggestive of ongoing infection. Multiple possible aetiologies were considered but given the patient's history of previous unresolved fungal infection, progressive disease was deemed most likely. The patient had previously grown a single yeast-like fungal organism culture on bronchoalveolar lavage (BAL). All other fungal cultures, including Aspergillus polymerase chain reaction (PCR), were negative. Pneumocystis jirovecii pneumonia (PJP) PCR and all other general microbiology also returned negative.
The initial spike in bilirubin (total) level was noted on day 5 post FLAG-AMSA to be 25 mm/L (normal high <21 mm/L) and peaked at 36 mm/L on day 7 (Figure 1(b) ). Upon routine monitoring of posaconazole trough levels, this rise in bilirubin had coincided with a drop in posaconazole level from 0.84 mg/L to 0.40 mg/L (Figure 1(c) ). At this point, the patient would have received 12 days of posaconazole tablets. Albumin level was consistently low averaging at about 25 g/L* throughout the patient's hospital stay (Figure 1(a) ). There were no identifiable cause of malabsorption, e.g. diarrhoea, vomiting, etc. as assessed by the hematology and nutrition teams. No drug interactions with posaconazole were identified during the remaining course of patient's hospital stay.
Outcome
The case was discussed between the treating hematology unit and the hematology pharmacist and then referred to the infectious diseases unit. The initial decision was to increase the dose of posaconazole tablet to 400 mg daily which was consistent with local hospital policy. This took into account the patient's (lean) body weight of 101 kg and a recent sub-therapeutic steadystate trough level of 0.40 mg/L. The repeat trough level after eight further days of treating with the 400 mg dose was 0.45 mg/L.
Posaconazole was replaced with voriconazole empirically, starting with a loading dose of 400 mg IV twice a day for the first 24 h, then changed to 300 mg IV twice a day for five days, and then switched to 250 mg orally twice a day as per local guidelines. Steady-state trough level taken after seven days of starting voriconazole and was 7.76 mg/L (target range 1-5.5 mg/L). The dose was decreased to 200 mg oral twice a day and after a further six days on this dose, repeat trough level remained supra-therapeutic at 6.02 mg/L.
Discussions
The reported posaconazole levels in this study represent total concentration of bound and unbound drug. A reduced level, as identified in our patient, can be the result of impaired absorption or increased metabolism and clearance. Although there are some reports of cases of auto-induction with voriconazole, a literature search did not retrieve any such reports for posaconazole. We also did not find any reports of other possible mechanism which could explain this rate of enhanced drug clearance.
Posaconazole is reported to be up to 98% bound to plasma proteins, predominantly albumin. 6 Experience with other highly plasma protein bound drugs such as phenytoin indicates that acute hypoalbuminaemia can result in a shift in the binding equilibrium and result in a reduced 'bound' fraction and therefore an increased 'unbound' fraction. However, the 'total' plasma posaconazole level would remain unchanged. 13 Further to this, a significant increase in serum bilirubin may compete for binding to serum albumin and displace a fraction of the 'bound' drug leading to further increase in the 'unbound' fraction. 13 At the time of writing, our liquid chromatography-mass spectrometry equipment could not detect the 'unbound' fraction independently. As a result, we were not able to report on the increased 'unbound' posaconazole levels.
As only the unbound fraction can undergo metabolism, this will potentially expose posaconazole to a greater extent of phase 1 and 2 metabolism and result in a greater overall drug clearance. 5 Another possibility is that substantial albumin loss, due to disease state, and vigorous albumin replacement could result in considerable loss of 'bound' posaconazole reserves. As the bound fraction is the major proportion of serum posaconazole, such effect will have a detrimental impact on the total drug concentration.
Bilirubin relies on glucuronidation for its excretion and elimination. This process usually occurs in the liver and the gastrointestinal system. Glucuronidated bilirubin, also known as 'conjugated bilirubin', is excreted in bile and eliminated in faeces. In hyperbilirubinemia, increased free serum bilirubin concentration can result in increased glucuronidation and potential upregulation of this pathway. This enhanced phase 2 metabolism has the potential to increase glucuronidation of posaconazole and subsequently enhance its elimination. 14, 15 In addition, it has been observed that after administration of posaconazole delayed-release tablets, up to 77% of a dose was eliminated in faeces, unchanged. 6 As conjugated bilirubin undergoes bacterial mediated de-conjugation in the gastrointestinal tract, the upregulated process can result in increased recycled glucuronic acid. This can result in further glucuronidation and decreased gastrointestinal absorption of posaconazole.
Conclusion
Failure to achieve target posaconazole levels despite increased dosing may be attributed to factors other than impaired oral absorption. Enhanced metabolism and clearance could be associated with hypoalbuminemia and hyperbilirubinemia. In the absence of other clinical data, we propose that this may explain the persistence of low posaconazole levels in the described patient. Further case studies, including PK modelling, are required to confirm this effect.
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